Skip to main content

Market Overview

Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox

  • Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults temporarily to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).
  • A California court case filed by Medytox against Evolus will be dismissed.
  • Under the terms of the settlement agreements, AbbVie and Medytox will release all claims against Evolus related to the alleged misappropriation of Medytox's trade secrets and grant a license to Evolus to continue to commercialize Jeuveau in the U.S. and Nuceiva.
  • AbbVie and Medytox will receive milestone and royalty payments from Evolus. Besides, Evolus will issue common stock to Medytox.
  • Price Action: EOLS gained sharply by 45.3% at $10.05, while ABBV is down 0.53% at $105.5 in market trading hours on last check Friday. 

Related Articles (ABBV + EOLS)

View Comments and Join the Discussion!

Posted-In: Biotech News Small Cap Legal General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at